dengu
viru
denv
flavivirida
famili
singl
positivestrand
rna
viru
transmit
aed
aegypti
aed
albopictu
mosquito
object
studi
investig
use
chloroquin
clq
antivir
drug
dengu
viru
monkey
analyz
action
drug
vivo
nonhuman
primat
group
aotu
azarai
infulatu
inocul
subcutan
inject
virul
strain
treat
untreat
clq
blood
hematolog
viremia
serum
biochem
valu
obtain
treat
untreat
four
receiv
clq
one
mockinfect
aotu
monkey
monkey
serum
sampl
day
postinocul
assay
revers
transcript
polymeras
chain
reaction
cytometr
bead
array
determin
viremia
inflammatori
cytokin
respect
addit
bodi
temperatur
activ
level
determin
present
work
clq
effect
replic
aotu
monkey
time
viremia
reduct
observ
compar
control
concentr
tumor
necrosi
factor
alpha
interferon
gamma
serum
anim
statist
signific
reduct
group
treat
clq
infect
compar
control
signific
decreas
system
level
liver
enzym
aspart
aminotransferas
ast
also
observ
anim
treat
clq
infect
compar
control
result
suggest
clq
interfer
replic
aotu
monkey
engu
fever
df
mosquitoborn
viral
diseas
caus
four
close
relat
dengu
viru
serotyp
genu
flaviviru
famili
flavivirida
includ
number
import
human
pathogen
denv
positivesens
singlestrand
rna
genom
approxim
kb
length
encod
open
read
frame
orf
nearli
nucleotid
process
proteas
viral
cellular
origin
three
structur
proteinscapsid
c
premembran
prm
envelop
e
seven
nonstructur
requir
replic
viru
four
serotyp
transmit
human
higher
primat
infect
aed
spp
mosquito
dengu
viru
caus
import
arthropodborn
viral
diseas
world
character
wide
spectrum
clinic
manifest
rang
flulik
diseas
dengu
fever
lifethreaten
diseas
known
dengu
hemorrhag
fever
dengu
shock
syndrom
dhfdss
avail
way
control
dengu
vector
control
sinc
licens
vaccin
effect
antivir
therapi
current
avail
denv
infect
capsid
c
protein
involv
viru
genom
membran
envelop
e
embed
lipid
bilay
viral
envelop
e
glycoprotein
major
surfac
protein
viru
respons
attach
entri
envelop
e
precursor
membran
prm
protein
major
structuralprotein
target
antibodi
respons
dengu
infect
lipid
composit
viral
envelop
dictat
composit
host
cell
membran
viru
emerg
two
type
virion
known
matur
extracellular
virion
contain
protein
immatur
intracellular
virion
contain
precursor
prm
proteolit
cleav
matur
product
glycoprotein
dengu
virus
enter
target
cell
via
receptormedi
endocytosi
direct
interact
viral
e
glycoprotein
host
cell
receptor
includ
dcspecif
nonintegrin
dcsign
mannos
receptor
follow
acid
phdepend
fusion
membran
endocyt
vesicl
expos
acid
ph
insid
endosom
vesicl
target
cell
viru
suffer
import
structur
modif
envelop
protein
includ
trimer
glycoprotein
e
domain
ii
rearrang
allow
project
viral
envelop
surfac
expos
fusion
domain
chloroquin
clq
known
sinc
diprot
weak
base
increas
ph
acid
organel
endosom
golgi
vesicl
lysosom
virus
clq
led
inhibit
lowphdepend
entri
step
alter
posttransl
modif
newli
synthes
protein
especi
via
inhibit
glycosyl
limit
infect
replic
denv
nonhuman
speci
hamper
lack
develop
anim
model
denv
infect
numer
anim
model
limit
use
potenti
dengu
model
thu
present
studi
evalu
action
clq
replic
aotu
azarai
infulatu
monkey
nonhuman
primat
nhp
phylogenet
close
human
chosen
experiment
model
studi
studi
carri
strict
accord
brazilian
govern
ethic
anim
experi
regul
procedur
use
anim
research
project
specifi
accord
ethic
principl
establish
brazilian
colleg
anim
experiment
cobea
experiment
protocol
approv
committe
ethic
anim
experi
univers
sao
paulo
ceteausp
permit
protocol
number
ministri
environ
mmasisbio
permit
protocol
number
surgeri
perform
ketamin
xylazin
anesthesia
effort
made
minim
anim
suffer
vero
cell
continu
cell
lineag
origin
kidney
african
green
monkey
grown
cultur
medium
invitrogen
new
york
supplement
fetal
bovin
serum
fb
lglutamin
mm
penicillin
g
iuml
streptomycin
lgml
triptos
phosphat
vero
cell
maintain
co
aed
albopictu
cell
line
cultur
medium
supplement
fb
lglutamin
triptos
phosphat
penicillin
g
uml
streptomycin
lgml
absenc
co
parent
new
guinea
c
strain
recov
brain
suckl
swiss
mice
use
studi
anim
sacrif
brain
remov
steril
environ
brain
homogen
bovin
skin
gelatin
sigmaaldrich
st
loui
mo
macer
harvest
centrifug
g
min
centrifug
macer
supernat
fluid
kept
ice
prevent
microbi
loss
divid
aliquot
store
frozen
viru
stock
supernat
fluid
use
present
studi
free
lipopolysaccharid
mycoplasma
viru
product
titrat
plaqu
assay
use
vero
cell
vero
cell
seed
plate
cellswel
medium
fb
h
medium
remov
decim
serial
dilut
viru
stock
ad
mlwell
cell
incub
h
subsequ
medium
contain
fb
carboxymethylcellulos
mlwell
overlay
ad
plate
incub
day
overlay
remov
day
cell
fix
solut
formaldehyd
pb
h
room
temperatur
formaldehyd
solut
remov
cell
wash
twice
pb
stain
min
crystal
violet
solut
ethanol
plaqu
cell
lysi
count
viru
concentr
express
plaqueform
unit
pfu
per
millilit
twentyon
male
monkey
speci
aotu
azarai
infulatu
year
old
weigh
kg
use
studi
anim
kept
coloni
nhp
nation
primat
centercenpsvsm
locat
biolog
reserv
typic
veget
amazon
rainforest
area
approxim
ha
district
ananindeua
brazil
institut
current
squad
primat
belong
amazon
region
atlant
rainforest
one
speci
old
world
coloni
good
reproduct
capac
thu
constitut
stabl
sourc
product
anim
use
experiment
studi
anim
infect
individu
hous
stainless
steel
cage
wire
mesh
bottom
monkey
fed
twice
daili
commerci
chow
supplement
fresh
fruit
egg
veget
water
ad
libitum
temperatur
humid
lightdark
cycl
standard
anim
identifi
microchip
specif
tattoo
mark
inner
side
right
hind
limb
anim
protocol
five
letter
accord
record
cenp
first
two
letter
repres
speci
name
ah
last
three
repres
individu
start
experi
biochem
hematolog
paramet
anim
evalu
complet
blood
count
serum
glucos
cholesterol
total
bilirubin
alanin
aminotransferas
alt
aspart
aminotransferas
ast
alkalin
phosphatas
ap
establish
normal
valu
physiolog
characterist
aim
use
speci
establish
experiment
model
dengu
also
anim
weigh
use
digit
scale
temperatur
anim
measur
prior
initi
studi
monkey
sera
analyz
antidengu
immunoglobulin
g
igg
antibodi
enzymelink
immunosorb
assay
elisa
indirect
elisa
perform
determin
presenc
antidengu
igg
five
group
monkey
day
end
experi
cell
supernat
fluid
use
antigen
dengu
igg
elisa
antigen
dilut
coat
buffer
carbonatebicarbon
buffer
ph
eia
flat
bottom
high
bind
micropl
corn
costar
corn
ny
coat
antigen
incub
overnight
period
plate
wash
three
time
pb
buffer
contain
tween
plate
block
prevent
fals
posit
result
ad
pb
buffer
sbf
incub
h
wash
three
time
pb
buffer
contain
tween
prepar
plate
test
sera
control
serum
posit
control
dilut
pb
buffer
sbf
llwell
ad
duplic
plate
plate
incub
h
period
plate
wash
six
time
pb
buffer
contain
tween
llwell
peroxidaseconjug
antimonkey
igg
goat
igg
sigmaaldrich
pb
sbf
ad
plate
plate
incub
h
incub
plate
wash
six
time
pb
contain
tween
follow
initi
peroxidas
reaction
addit
llwell
substrat
solut
tmb
plate
plate
incub
room
temperatur
min
dark
reaction
stop
ad
llwell
phosphor
acid
optic
densiti
read
perform
elisa
reader
excit
wavelength
nm
refer
filter
nm
threshold
cutoff
calcul
mean
od
neg
control
plu
three
time
standard
deviat
sd
sampl
cutoff
consid
posit
differ
concentr
clq
mgkg
administ
oral
rout
aotu
monkey
accord
use
human
drug
also
prepar
laminar
flow
hood
dilut
salin
dengu
aotu
monkey
n
use
experi
randomli
divid
five
group
four
anim
one
control
anim
ahair
receiv
control
macer
supernat
fluid
brain
suckl
swiss
mice
stock
mock
infect
anim
kept
separ
cage
control
environment
condit
anim
fed
describ
procedur
perform
anesthesia
mgkg
ketamin
chlorid
vetaset
fort
dodg
ia
intramuscularli
anim
infect
subcutan
sc
ml
pfuml
suspens
upper
arm
blood
collect
daili
femor
vein
day
detect
viremia
infect
analysi
biochem
hematolog
paramet
complet
blood
count
alt
ast
ap
group
receiv
dose
clq
oral
mgkg
day
dose
mgkg
day
dose
mgkg
day
group
control
anim
infect
sc
group
receiv
dose
clq
mgkg
h
later
infect
sc
group
receiv
dose
clq
mg
kg
day
dose
mgkg
day
dose
mgkg
day
group
infect
sc
h
later
receiv
dose
clq
mgkg
day
dose
mgkg
day
dose
mgkg
day
group
infect
sc
h
later
receiv
dose
clq
mgkg
twice
per
day
day
dose
mgkg
twice
per
day
day
dose
mgkg
twice
per
day
day
studi
conduct
styer
et
al
use
wnv
show
mosquito
inocul
pfu
wnv
per
bite
similar
level
transmiss
observ
denv
infect
anim
pfu
denv
usual
consid
mimic
inoculum
mosquito
bite
nhp
sustain
viral
replic
sc
inocul
dose
pfu
denv
howev
viral
replic
much
lower
human
viral
rna
extract
serum
sampl
use
qiaamp
viral
rna
kit
qiagen
valencia
ca
accord
manufactur
direct
amplif
fragment
serum
aotu
monkey
perform
use
revers
transcriptas
polymeras
chain
reaction
rtpcr
assay
rtpcr
contain
buffer
dntp
mm
multiscrib
ull
primer
nm
gtg
aga
tga
agc
tgt
agt
tcc
att
ttc
tgg
cgt
specif
design
anneal
untransl
region
depc
water
rna
final
volum
amplif
protocol
consist
follow
step
min
min
follow
cycl
min
min
min
final
min
experi
carri
duplic
blood
drawn
daili
next
day
serum
collect
immedi
frozen
subsequ
determin
cytokin
product
assay
perform
flow
cytometri
applic
allow
quantif
multipl
cytokin
simultan
interferon
gamma
ifnc
tumor
necrosi
factor
alpha
tnfa
measur
serum
use
cytometr
bead
array
cba
method
nonhuman
primat
cytokin
kit
ii
bd
recommend
manufactur
experi
carri
duplic
result
shown
mean
valu
obtain
two
individu
experi
monkey
observ
day
end
experi
rectal
temperatur
weight
hematolog
paramet
biochem
paramet
record
monkey
releas
coloni
statist
analysi
use
assess
differ
cytokin
product
liver
enzym
timedefin
interv
serum
monkey
infect
contact
clq
day
viremia
mock
infect
fluid
macer
supernat
brain
suckl
swiss
mice
dengu
viru
serotyp
stock
anim
use
control
control
group
without
drug
use
twoway
analysi
varianc
anova
test
multipl
comparison
test
descript
statist
mean
standard
deviat
use
hematolog
paramet
compar
mean
group
use
twoway
anova
test
data
enter
graphpad
prism
softwar
analys
pvalu
consid
statist
signific
result
elisa
assay
anim
serum
sampl
obtain
prior
initi
studi
submit
antidengueigg
analysi
show
neg
igg
sampl
anim
group
two
anim
group
one
anim
group
posit
igg
serum
sampl
obtain
day
end
experi
tabl
tabl
present
result
obtain
viremia
evalu
aotu
monkey
infect
uninfect
treat
untreat
clq
five
experiment
group
group
anim
infect
untreat
induc
viremia
four
monkey
durat
day
mean
durat
daysanim
group
anim
infect
treat
clq
induc
reduct
time
viremia
four
anim
durat
day
mean
durat
daysanim
compar
control
group
form
anim
infect
treat
twice
per
day
clq
viremia
detect
two
anim
ahbbr
ahbaf
wherea
monkey
present
day
viremia
mean
durat
dayanim
compar
control
group
anim
receiv
prophylact
dose
clq
h
later
infect
viremia
detect
one
anim
ahaki
wherea
monkey
present
day
viremia
mean
durat
dayanim
compar
control
e
f
cytokin
product
infect
uninfect
anim
treat
untreat
clq
analyz
flow
cytometri
allow
multipl
cytokin
quantifi
simultan
analys
pvalu
consid
statist
signific
untreat
fig
b
statist
signific
differ
observ
product
cytokin
group
compar
control
fig
anim
ahair
inocul
mock
macer
supernat
fluid
brain
suckl
swiss
mice
dengu
viru
serotyp
stock
use
present
studi
fail
produc
cytokin
product
ifnc
tnfa
significantli
reduc
p
presenc
clq
compar
control
demonstr
clq
abl
reduc
viral
yield
group
fig
b
fever
weight
none
monkey
show
chang
temperatur
averag
temperatur
weight
averag
weight
kg
hematolog
paramet
none
monkey
show
chang
hematolog
paramet
complet
blood
count
tabl
biochem
paramet
alt
ast
commonli
use
biomark
liver
damag
signific
decreas
serum
ast
activ
observ
day
anim
treat
clq
compar
control
p
fig
neither
serum
alt
ap
activ
alter
compar
control
fig
c
nhp
use
investig
sever
aspect
denv
studi
includ
involv
effect
natur
experiment
infect
studi
immun
respons
anim
infect
viru
studi
evalu
number
vaccin
candid
denv
gener
specif
antibodi
denv
kinet
viremia
monkey
shown
essenti
similar
observ
human
infect
denv
studi
aotu
azarai
infulatu
also
demonstr
detect
specif
antibodi
presenc
viremia
anim
similar
observ
human
infect
denv
nhp
infect
denv
consid
accept
anim
model
studi
virolog
immunolog
aspect
experiment
infect
import
except
use
monkey
experiment
model
anim
infect
denv
develop
detect
sign
diseas
includ
manifest
rang
classic
df
sever
case
dhf
dss
characterist
human
infect
viru
viremia
one
major
clinic
manifest
dengu
viru
infect
present
studi
show
anim
group
present
viremia
day
group
treat
clq
gradual
declin
undetect
level
viremia
compar
anim
group
tabl
suggest
drug
effect
infect
speci
anim
studi
studi
vivo
nhp
conduct
almost
exclus
hiv
clq
current
evalu
tabl
hematolog
paramet
express
mean
statist
signific
reduct
viral
load
wherea
patient
undetect
level
viral
dna
increas
cell
count
studi
support
hypothesi
clq
may
applic
prevent
transmiss
hiv
mother
child
breast
milk
studi
report
accumul
clq
time
colostrum
cell
hivinfect
african
mother
took
clq
mg
per
day
suggest
drug
may
potenti
activ
adjunct
antivir
prophylaxi
postnat
transmiss
mother
child
decreas
burden
breast
milk
geograph
area
transmiss
higher
onlamoon
et
al
observ
peak
dengu
viremia
infect
rhesu
monkey
day
infect
regard
biochem
paramet
decreas
level
liver
enzym
ast
observ
serum
anim
treat
clq
compar
posit
control
fifth
sixth
day
infect
fig
chang
found
hematolog
paramet
anim
infect
anim
monitor
show
chang
weight
temperatur
experi
similar
result
observ
onlamoon
et
al
anim
show
appar
clinic
symptom
fever
inappet
lethargi
monkey
group
significantli
higher
level
ifnc
tnfa
recent
studi
demonstr
dengueinfect
individu
significantli
higher
level
tnfa
ifnc
mda
compar
control
group
anim
infect
treat
drug
statist
signific
reduct
detect
ifnc
tnfa
fig
b
previou
studi
demonstr
block
proinflammatori
cytokin
clq
shown
protect
inflamm
andor
sepsi
induc
lp
dna
escherichia
coli
mice
karr
et
al
show
clq
also
inhibit
cytokin
releas
human
whole
blood
effect
could
benefici
diseas
relat
inflamm
induc
bacteria
antiinflammatori
properti
clq
may
protect
effect
treatment
patient
lupu
erythematosu
nishimura
et
al
analyz
immunosuppress
effect
clq
effect
potenti
exploit
improv
condit
patient
chronic
graftversushost
posttransfus
respons
induc
dengu
viru
may
trigger
inflammatori
cytokin
respons
dengu
sever
preliminari
result
obtain
studi
show
clq
suppress
tnfa
ifnc
product
hypothes
clq
may
use
treat
patient
suspect
dengu
diseas
avoid
sever
form
diseas
dengu
hemorrhag
fever
andor
shock
dengu
shock
syndrom
recent
studi
show
chloroquin
promot
reduct
intens
pain
improv
wellb
patient
dengu
infect
alter
durat
diseas
intens
day
fever
result
suggest
clq
test
dengu
diseas
larger
number
patient
differ
clq
dosag
time
administr
confirm
drug
clinic
effect
assess
side
effect
clq
dengu
patient
presenc
igg
antidengu
antibodi
serum
anim
show
anim
abl
respond
infect
denv
occur
human
absenc
igg
antibodi
specif
antidengu
serum
anim
receiv
clq
infect
demonstr
efficaci
drug
prophylact
treatment
group
anim
treat
clq
infect
individu
respons
observ
show
drug
also
effect
therapeut
treatment
anim
therefor
model
nhp
infect
denv
provid
valuabl
tool
detail
studi
viru
infect
also
provid
comprehens
analysi
virushost
interact
potenti
lead
identif
cellular
molecular
mechan
lead
dengu
fever
replic
viru
taken
togeth
data
obtain
studi
result
suggest
clq
interfer
viru
replic
aotu
monkey
howev
rel
safe
drug
effect
easi
purchas
use
treatment
mani
diseas
includ
malaria
therapeut
use
promis
shown
drug
signific
inhibitori
antivir
effect
replic
